Tenaya Therapeutics, Inc.
NASDAQTenaya Therapeutics heads into today's earnings print with one of the most elevated short scores in the biotech universe — yet the stock has been climbing. The short side is deeply embedded here. Short interest runs at 16.1% of the free float, and while it has eased about 7% over the past week, it still sits roughly 24% above where it was a month ago. The ORTEX short score of 74.7…
Snapshot as of 7 May 2026
Tenaya Therapeutics heads into today's earnings print with one of the most elevated short scores in the biotech universe — yet the stock has been climbing. The short side is deeply embedded here. Short interest runs at…
Tenaya Therapeutics reported Q1 2026 results just after Wednesday's close. The headline number landed on both sides of the ledger — EPS of -$0.09 missed the -$0.06 estimate, but revenue of $25 million crushed the $10…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TNYA — free to start on ORTEX.
Sign up for free →Open TNYA on ORTEX